All In Biotech

Drug Trial Radar · NCT06794554

Rezafungin for Treatment of Chronic Pulmonary Aspergillosis (CPA) in Adults With Limited Treatment Options

A Phase 2, Multicentre, Open-label, Single Arm Study to Evaluate the Effectiveness and Safety of Rezafungin (as Acetate) in the Treatment of Chronic Pulmonary Aspergillosis (CPA) in Patients With Limited Treatment Options

Last checked: Nov 19, 2026Latest source record: May 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Jun 30, 2025

Primary completion

Nov 30, 2026

Study completion Dec 30, 2026

Sponsor

Lead sponsor
Mundipharma Research LimitedIndustry
Sponsor type
Industry
First posted
Jan 27, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to to evaluate the drug rezafungin in the treatment of Chronic Pulmonary Aspergillosis (CPA) in male and female patients aged 18 years and over with limited treatment options. The study aims to answer whether 6 months of rezafungin treatment is effective and safe in patients with chronic pulmonary aspergillosis with limited treatment options according to clinical and radiological response as measured by the St George's Respiratory Questionnaire, weight, and CT imaging. Participants will: * Be given the drug rezafungin every week for 6 months. * Visit the clinic once a month for checkups and tests. * Complete questionnaires on thier health and wellbeing.

Conditions

  • Chronic Pulmonary Aspergillosis

Interventions

  • Rezafungin AcetateDrug

    IV with a 400 mg loading dose on Day 1 of Week 1, followed by 200 mg once weekly, for a total of 26 doses (6 months).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in clinical and radiological response at 6 monthsTime frame: 6 months

Locations

37 sites in 10 countries. Site status is shown where the registry gives one.

  • Kepler University Hospital

    Linz, Austria

  • Brussels University Hospital

    Brussels, Belgium

  • UZ Gent

    Ghent, Belgium

  • University Hospital Leuven

    Leuven, Belgium

  • CHU UCL Namur

    Yvoir, Belgium

  • CHU Amiens Picardie

    Amiens, France

  • Institut Coeur Poumon CHU

    Lille, France

  • CHU Arnaud de Villeneuve

    Montpellier, France

  • CHU Bordeaux

    Pessac, France

  • Evangelische Lungenklinik Berlin

    Berlin, Germany

  • University of Cologne

    Cologne, Germany

  • Asklepios Lungenfachklinik Gauting

    Gauting, Germany

  • Országos Korányi Pulmonológiai Intézet

    Budapest, Hungary

  • University of Genova, San Martino Hospital

    Genova, Italy

  • University of Pisa

    Pisa, Italy

  • INMI Lazzaro Spallanzaniconsu

    Roma, Italy

  • Humanitas Research Hospital

    Rozzano, Italy

  • Radboud Universitair Medisch Centrum Stichting

    Nijmegen, Netherlands

  • Chonnam National University Hospital

    Gwangju, South Korea

  • Seoul National University Bundang Hospital

    Seoul, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

  • Severance Hospital, Yonsei University Health System

    Seoul, South Korea

  • Hospital de la Santa Creu i Sant Pau

    Barcelona, Spain

  • Hospital Universitari de Bellvitge

    Barcelona, Spain

  • Vall d'Hebron Barcelona Hospital Campus

    Barcelona, Spain

  • Ramón y Cajal Hospital

    Madrid, Spain

  • Hospital Sant Joan de Deu de Martorell

    Martorell, Spain

  • Hospital La Fe

    Valencia, Spain

  • Royal Papworth Hospital

    Cambridge, United Kingdom

  • University Hospitals of Derby and Burton

    Derby, United Kingdom

  • University of Dundee

    Dundee, United Kingdom

  • Western General Hospital

    Edinburgh, United Kingdom

  • Leeds Teaching Hospital

    Leeds, United Kingdom

  • Imperial College Hospital

    London, United Kingdom

  • Royal Brompton Hospital, Guy's and St. Thomas' Hospital

    London, United Kingdom

  • University College London (UCL) Hospitals

    London, United Kingdom

  • Manchester University Hospital

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.